Global Excellence 2019

Acquisition International - Global Excellence 2019 199 Acquisi International - Issu 8 2019 21 Delivering Personalized Medicine Through Molecular Diagnostics and Innovation Overall the firm’s mission is to provide important supplemental information following common first line tests to help mitigate diagnostic uncertainty. Providing the firm with the ability and opportunity to fulfil this mission is the innovative, committed and passionate team which forms the backbone of Interpace Diagnostics. When discussing the internal culture, Greg is keen to highlight the significant role the teams play in the overall success of the firm. “All 100 members of our team are critical to the success of the Company; from our lab Operations team to Client Services, Commercial, and our Corporate Leadership team, we are all focused on our primary mission - to eliminate diagnostic uncertainty and improve patient care and outcomes. We often recognize individuals and teams for extraordinary performance or contributions to a particular focus or priority for the Company.” Looking ahead to what the future holds for the firm, the team at Interpace Diagnostics hope to build upon their advancements within the industry and their accomplishments, especially following their recent success in Acquisition Intl.’s (AI) Global Excellence Awards 2019 where they were righteously awarded the accolade Most Innovative Molecular Diagnostics Company 2019 – Northeast USA. Bringing the interview to a close, Greg signs off by revealing the exciting plans which lie in the pipeline for the firm, noting how the company will complete clinical studies and publish papers in the years to come. “Moving forward, we will be launching product extensions and expanding indications for some of our current products. In addition, we are starting large-scale studies that will further validate our current products. Lastly, we will also be publishing papers in peer-reviewed publications and will be speaking at and participating in several key industry sponsored conferences including the American Thyroid Association and the American College of Gastroenterology.” Ultimately, Interpace Diagnostics is consistently growing and at a rapid rate. The future looks promising for the company as they continue to dedicate their time and services to improving patient care through unparalleled insights which have been provided by their proprietary suite of products. As such, Interpace Diagnostics’ success has been a result of the confidence that their customers have in that information. “...we will also be publishing papers in peer-reviewed publications and will be speaking at and participating in several key industry sponsored conferences including the American Thyroid Association and the American College of Gastroenterology.” Most Innovative Molecular Diagnostics Testing Comp ny 2019 - Northeast USA